Charles Zhu
Stock Analyst at LifeSci Capital
(2.48)
# 2,277
Out of 4,834 analysts
24
Total ratings
47.62%
Success rate
13.62%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Charles Zhu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RPTX Repare Therapeutics | Downgrades: Market Perform | n/a | $1.33 | - | 1 | Dec 13, 2024 | |
| TNGX Tango Therapeutics | Maintains: Buy | $18 → $8 | $1.52 | +426.32% | 3 | Nov 7, 2024 | |
| MGNX MacroGenics | Upgrades: Buy | $12 | $1.54 | +679.22% | 4 | Nov 7, 2023 | |
| MRUS Merus | Maintains: Buy | $46 → $48 | $40.08 | +19.76% | 6 | Aug 8, 2023 | |
| NUVL Nuvalent | Initiates: Buy | $56 | $71.05 | -21.18% | 1 | Jul 24, 2023 | |
| TARA Protara Therapeutics | Assumes: Buy | $22 | $3.11 | +607.40% | 1 | Jul 10, 2023 | |
| COGT Cogent Biosciences | Reiterates: Buy | $26 | $4.76 | +446.22% | 3 | Jun 13, 2023 | |
| IDYA IDEAYA Biosciences | Reiterates: Buy | $32 | $17.32 | +84.76% | 3 | Mar 8, 2023 | |
| ZYME Zymeworks | Upgrades: Buy | $14 | $11.53 | +21.42% | 2 | May 5, 2022 |
Repare Therapeutics
Dec 13, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $1.33
Upside: -
Tango Therapeutics
Nov 7, 2024
Maintains: Buy
Price Target: $18 → $8
Current: $1.52
Upside: +426.32%
MacroGenics
Nov 7, 2023
Upgrades: Buy
Price Target: $12
Current: $1.54
Upside: +679.22%
Merus
Aug 8, 2023
Maintains: Buy
Price Target: $46 → $48
Current: $40.08
Upside: +19.76%
Nuvalent
Jul 24, 2023
Initiates: Buy
Price Target: $56
Current: $71.05
Upside: -21.18%
Protara Therapeutics
Jul 10, 2023
Assumes: Buy
Price Target: $22
Current: $3.11
Upside: +607.40%
Cogent Biosciences
Jun 13, 2023
Reiterates: Buy
Price Target: $26
Current: $4.76
Upside: +446.22%
IDEAYA Biosciences
Mar 8, 2023
Reiterates: Buy
Price Target: $32
Current: $17.32
Upside: +84.76%
Zymeworks
May 5, 2022
Upgrades: Buy
Price Target: $14
Current: $11.53
Upside: +21.42%